Danielle Mclaughlin is a Columbia, Missouri based female Ophthalmologist who is specialized in Ophthalmology. Active license number of Danielle Mclaughlin is 2023023776 for Ophthalmology in Missouri. Danielle Mclaughlin is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Danielle Mclaughlin speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Ophthalmology
Credentials:
MD
Gender:
Female
Practice Address:
1 Hospital Dr, Columbia, Missouri, 65212-1000
Phone:
573-882-4688
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1932886769
NPI Enumeration Date:
03 Jul, 2023
NPI Last Update On:
03 Jul, 2023
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Danielle Mclaughlin are as mentioned below.
License Number
Specialization
State
Status
2023023776
Ophthalmology
Missouri
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1 Hospital Dr # 52.00, Columbia, Missouri
Zip:
65212-1000
Phone Number:
--
Fax Number:
--
Patients can reach Danielle Mclaughlin at 1 Hospital Dr, Columbia, Missouri or can call to book an appointment on 573-882-4688. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.